Ciphergen, Beckman Coulter Alliance Hopes to Automate Proteomics Research | GenomeWeb

NEW YORK, March 5 - Ciphergen Biosystems and Beckman Coulter on Tuesday said they plan to automate clinical proteomics research.

Terms of the agreement call for Ciphergen to combine its SELDI protein chip biomarker system with a custom version of Beckman's Biomek 2000 system. The resulting "turnkey" platform will be marketed to industry, academia, and government institutes, the companies said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.